TAF7 and nonpapillary renal cell carcinoma: Consistent with previous reports, our results indicated that TAF7 silencing inhibited ccRCC progression through reducing cell activity, increasing apoptosis, arresting S into G2/M cell cycle and diminishing migration, which substantiated the oncogenic capacity of TAF7 in ccRCC.